06 October 2020: Database Analysis
Creation of a Prognostic Risk Prediction Model for Lung Adenocarcinoma Based on Gene Expression, Methylation, and Clinical Characteristics
Honggang Ke 1CD* , Yunyu Wu 2DEF* , Runjie Wang 3CDF , Xiaohong Wu 4AB*DOI: 10.12659/MSM.925833
Med Sci Monit 2020; 26:e925833
Table 2 Clinical information from The Cancer Genome Atlas (TCGA) and GSE62254 datasets.
| Clinical characteristics | TCGA (N=335) | GSE37745 (N=106) |
|---|---|---|
| Age (years, mean±SD) | 65.19±10.25 | 62.94±9.22 |
| Sex (Male/Female) | 155/180 | 46/60 |
| Pathologic M (M0/M1/–) | 226/13/96 | – |
| Pathologic N (N0/N1/N2/–) | 214/60/55/6 | – |
| Pathologic T (T1/T2/T3/T4/–) | 111/180/29/14/1 | – |
| Pathologic stage (I/II/III/IV) | 180/81/61/13 | 70/19/13/4 |
| Radiation therapy (yes/no/–) | 41/254/40 | – |
| Targeted molecular therapy (yes/no/–) | 99/194/42 | – |
| Tobacco smoking history (current/reformed/never/–) | 70/206/45/14 | – |
| Recurrence (yes/no/–) | 104/176/55 | 26/27 |
| Death (dead/alive) | 120/215 | 77/29 |
| Recurrence-free survival time (months, mean±SD) | 22.27±27.77 | 54.11±53.48 |
| Overall survival time (months, mean±SD) | 27.54±29.74 | 61.74±49.96 |
| ‘–’ – Represents information unavailable. | ||